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An acute increase in the international normalized ratio
(INR; a comparison of prothrombin time to monitor the
effects of warfarin) over 3 in patients with chronic kidney
disease (CKD) is often associated with an unexplained acute
increase in serum creatinine (SC) and an accelerated
progression of CKD. Kidney biopsy in a subset of these
patients showed obstruction of the renal tubule by red blood
cell casts, and this appears to be the dominant mechanism of
the acute kidney injury. We termed this warfarin-related
nephropathy (WRN), and previously reported cases of WRN
only in patients with CKD. We now assess whether this occurs
in patients without CKD, its risk factors, and consequences.
In 15,258 patients who initiated warfarin therapy during a
5-year period, 4006 had an INR over 3 and SC measured at
the same time; however, the large data set precluded
individual patient clinical assessment. A presumptive
diagnosis of WRN was made if the SC increased by over
0.3mg/dl within 1 week after the INR exceeded 3 with no
record of hemorrhage. WRN occurred in 20.5% of the entire
cohort, 33.0% of the CKD cohort, and 16.5% of the no-CKD
cohort. Other risk factors included age, diabetes mellitus,
hypertension, and cardiovascular disease. The 1-year
mortality was 31.1% with compared with 18.9% without
WRN, an increased risk of 65%. Thus, WRN may be a common
complication of warfarin therapy in high-risk patients and
CKD doubles this risk. The mechanisms of these risks are
unclear.
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Recently, we reported a renal biopsy study of nine patients on
warfarin therapy with unexplained acute kidney injury (AKI)
associated with increased international normalized ratio
(INR). Based on the renal biopsy findings, we concluded
that the AKI was caused by glomerular hemorrhage and renal
tubular obstruction by red blood cell casts.1 Each of these
patients had clinical and renal biopsy evidence of chronic
kidney disease (CKD) that predated the episode of AKI.
Because this form of AKI appeared to be associated with
CKD, we next undertook a retrospective analysis of 103
patients from our CKD population receiving warfarin
therapy. Of these, 49 patients developed an INR 43.0. Of
these, 18 patients (37%) experienced an unexplained increase
in serum creatinine (SC) X0.3mg/dl (mean increase
0.61±0.44mg/dl) within 1 week of the INR 43.0.2 These
patients also showed accelerated progression of their CKD,
as compared with those who did not experience an increase
in SC in relation to the INR 43.0. We have termed the
unexplained increase in SC associated with INR 43.0,
warfarin-related nephropathy (WRN).
The current study was undertaken to investigate further
the prevalence, risk factors, and consequence of WRN, with
emphasis on the extent to which WRN develops in CKD
compared with no-CKD patients. The large data set of the
present study precluded detailed individual patient clinical
assessment to assess whether an increase in SC acutely related
to an INR 43.0 was ‘unexplained’, as we were able to do in
our previous reports.1,2 However, we did require that the
patient’s medical record at the time of an INR 43.0 not
describe hemorrhage or blood transfusion. Thus, the present
work describes ‘presumptive’ WRN.
RESULTS
Identification of the study patients in the Ohio State
University Medical Center information warehouse database
The algorithm used to identify patients for this analysis is
provided in Materials and Methods. Briefly, the initial cohort
consisted of 15,258 patients who, based on their information
warehouse (IW) electronic medical record, received warfarin
therapy as an inpatient or outpatient at the Ohio State
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University Medical Center (OSUMC) between 1 January
2005 and 31 December 2009 (cohort 1). Out of those, 6019
patients had at least one episode of INR 43.0 recorded
during follow-up (cohort 2). If multiple episodes of INR
43.0 occurred, we used the first one for this analysis. In the
cohort 2 patients, SC was recorded within 1 week after the
first INR43.0 in 4848. They became cohort 3. Out of those,
4816 patients also had at least one SC recorded within 3
months before the first abnormal INR 43.0. They became
cohort 4. The final cohort (cohort 5) was selected by
application of the inclusion and exclusion criteria described
in Materials and Methods. This cohort consisted of 4006
patients. Cohort 5 consisted of 821 patients with presumptive
WRN (increase in SC X0.3mg/dl within 1 week of INR
43.0, 20.5% of cohort 5) and 3185 patients with no WRN
(no increase in SC X0.3mg/dl within 1 week of INR 43.0,
79.5% of cohort 5). An increase in SCX0.3 was taken as the
evidence of AKI based on the guidelines of the Acute Kidney
Injury Network.3 A patient was classified as a CKD patient if
one of the International Classification of Diseases-9 (ICD-9)
codes 585.1 through 585.5 or 585.9 was recorded in the
patient’s record. Patients with ICD-9 code 585.6 (end-stage
renal disease) were excluded from the final analysis.
INR and sequential changes in SC and estimated glomerular
filtration rate in WRN patients compared with no-WRN
patients
Figure 1a shows the INR values at the first episode of INR43.0
for the WRN and no-WRN patients. The INR values were
significantly higher in the WRN than no-WRN patients in
cohort 5 (4.44±2.46 versus 4.15±2.15 IU, P¼ 0.0009) and
for the no-CKD subset (4.57±2.69 versus 4.13±2.13 IU,
Po0.0001). However, for the CKD subset, there was no
difference in mean INR values at the first episode of INR43.0
between the WRN versus no-WRN patients (4.22±2.01 versus
4.22±2.224 IU P¼ 0.9569). There was no significant correla-
tion between the magnitude of SC changes and the degree of
elevation of INR 43.0 (data not shown).
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Figure 1 | International normalized ratio (INR) and changes in serum creatinine (SC) levels associated with INR increase X3.0 in
patients with and without warfarin-related nephropathy (WRN). Panel a shows that the INR for the first episode of INR 43.0 was
significantly higher in WRN patients than the no-WRN patients for cohort 5 (all patients) and for the no-CKD (chronic kidney disease)
subset but not the CKD subset. Panel b shows the changes in SC for cohort 5, stratified by the patient’s status as WRN (square) or no
WRN (circle). The mean SC±1 s.d. is shown for the following intervals: 0–3 months before and at the onset of INR 43.0 (arbitrarily
shown as 1 month before and at the onset of INR 43.0), 0–6 days after the INR 43.0 (arbitrarily shown as 6 days after the onset of INR
43.0), and 2–4 months after the INR 43.0 (arbitrarily shown as 3 months after the INR 43.0). The format for panels c and d is the
same as that of panel b, except that panel c shows the no-CKD cohort and panel d shows the CKD cohort. As shown, mean SC increased
significantly at onset of INR 43.0 in the WRN cohorts and tended to remain elevated 3 months later. SC values were available for all
patients within 6 days after the INR43.0. For the period 0–3 months after the INR43.0, SC values were available for 1917 of 2780 (69%) of
the surviving no-CKD and 611 of 722 (85%) of the surviving CKD patients. Longer-follow-up data are not shown because they were not
consistently available across the indicated cohorts. To convert SC in mg/dl to mol/l, multiply by 88.4. *Po0.05 compared with no-WRN
group, #Po0.05 compared with 0–3 months before INR 43.0. IU, international unit.
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Figure 1b shows the sequential changes in mean SC in the
cohort 5 patients, stratified by WRN, no-WRN status. As
shown, the mean SC at the onset of INR 43.0 was
significantly higher in the WRN patients than the no-WRN
patients (2.75±1.65 versus 1.17±0.71mg/dl, Po0.0001). By
3 months after the onset of WRN, the mean SC in the WRN
patients remained higher than that of the no-WRN patients
(1.80±1.24 versus 1.13±0.67mg/dl, Po0.0001). Some of
these differences are, however, attributable to a higher mean
SC in the period preceding the INR 43.0 in those that
developed WRN.
Figure 1c shows the sequential changes in mean SC in
the no-CKD patients, stratified by their WRN, no-WRN
status. As shown, at the onset of INR 43.0, mean SC was
significantly higher in the WRN patients than the no-WRN
patients (2.45±1.57 versus 1.01±0.49mg/dl, Po0.0001).
By 3 months after the onset of WRN, SC decreased in the
WRN patients but remained higher than that in the
no-WRN patients (1.52±1.08 versus 1.00±0.51mg/dl,
Po0.0001).
Figure 1d shows the sequential changes in mean SC in the
CKD patients, stratified by their WRN, no-WRN status. As
shown, at the onset of INR 43.0, mean SC was significantly
higher in the WRN patients than the no-WRN patients
(3.25±1.67 versus 1.79±1.09mg/dl, Po0.0001). By 3
months after the onset of WRN, mean SC in the WRN
patients remained higher than that of the no-WRN patients
(2.29±1.33 versus 1.65±0.94mg/dl, Po0.0001).
Histograms showing the distribution of INR and changes
in SC are depicted in Figure 2. As shown, using SC X0.3
mg/dl decisively separates WRN from no-WRN patients
(Figure 2a, c and e). Regarding INR distribution, the INR
values were slightly higher in WRN versus no-WRN patients
for the entire cohort (cohort 5); however, this finding was not
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Figure 2 |Histograms of the international normalized ratio (INR) and changes in serum creatinine (SC) distributions in patients with
and without warfarin-related nephropathy (WRN). Panels a, c, and e show the distribution of changes in SC (delta SC) in all patients
(cohort 5, panel a), patients without WRN (no WRN, Panel c), and WRN patients (Panel e). Panels b, d, and f show the distribution of INR in
all patients (cohort 5, panel b), patients without WRN (no WRN, panel d), and WRN patients (panel f). IU, international unit.
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consistent across the CKD and no-CKD cohorts, as discussed
above (Figure 2b, d and f).
Figure 3a shows changes in estimated glomerular filtration
rate (eGFR) inWRN and no-WRN patients; eGFR was calculated
based on the Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) equation.4 Figure 3b and c show eGFR changes
in CKD and no-CKD patients with and without WRN,
respectively. The dynamics in eGFR changes were similar to SC
changes—significant eGFR decrease in WRN patients with only a
partial recovery by 3 months after INR43.0 in CKD patients. In
no-CKD patients, eGFR was not significantly different from
pre-INR 43.0 levels (Figure 3b and c).
Baseline clinical characteristics of the WRN patients and the
no-WRN patients
Table 1 shows baseline clinical characteristics of cohort 5,
stratified by WRN, no-WRN status. As shown, WRN patients
did not differ from no-WRN patients with respect to sex and
race. However, the risk of WRN was significantly increased in
older patients and in those with CKD, diabetes, diabetic
nephropathy, hypertension, and heart failure. Patients with
an ICD-9 code for a specific kidney disease but without an
ICD-9 code for CKD were stratified into the no-CKD cohort.
These patients were more prevalent in WRN group, but the
overall number of these patients was small.
Table 2 shows baseline clinical characteristics of the WRN and
no-WRN cohorts, stratified by their CKD, no-CKD status.
Within the no-CKD cohort, there was no significant association
of age, sex, or race with WRN. However, diabetes, diabetic
nephropathy, hypertension, and heart failure were significantly
associated with WRN. For the patients with specific kidney
disease diagnoses, there was no clear association with WRN.
Within the CKD cohort, there was no significant association
of WRN with sex or race; however, older age was more prevalent
in the WRN cohort. The diagnosis of diabetes or diabetic
nephropathy did not increase the risk of WRN in the CKD
cohort. However, heart failure did increase the risk of WRN.
Specific renal disease diagnoses were not obviously different
between the WRN, no-WRN status of the CKD patients.
Hematuria and WRN
Figure 4 shows changes in dipstick hematuria in relation to
the onset of WRN. The method of comparison is described in
the figure legend. As can be seen from panel a, there were no
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Figure 3 |Changes in estimated glomerular filtration rate (eGFR) associated with international normalized ratio (INR) increase
X3.0 in patients with and without warfarin-related nephropathy (WRN). eGFR was calculated based on the chronic kidney disease
(CKD)-EPI equation. Panel a shows the changes in eGFR for cohort 5, stratified by the patient’s status as WRN (square) or no WRN (circle).
The mean eGFR±1 s.d. is shown for the following intervals: 0–3 months before and at the onset of INR 43.0 (arbitrarily shown as
1 month before and at the onset of INR43.0), 0–6 days after the INR43.0 (arbitrarily shown as 6 days after the onset of INR43.0), and 2–4
months after the INR43.0 (arbitrarily shown as 3 months after the INR43.0). The format for panels b and c is the same as that of panel a,
except that panel b shows the no-CKD cohort and panel c shows the CKD cohort. As shown, mean eGFR decreased significantly at onset of
INR 43.0 in the WRN cohorts and tended to remain reduced 3 months later. eGFR was calculated based on serum creatinine (SC)
values, which were available for all patients within 6 days after the INR43.0. For the period 0–3 months after the INR43.0, SC values were
available for 1917 of 2780 (69%) of the surviving no-CKD and 611 of 722 (85%) of the surviving CKD patients. Longer-follow-up data are not
shown because they were not consistently available across the indicated cohorts. *Po0.05 compared with no-WRN group, #Po0.05
compared with 0–3 months before INR 43.0.
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important differences in the extent of dipstick hematuria
from 1 week after the INR43.0 compared with 0–3 months
before the INR 43.0. As shown in panel b, there was no
important difference in the change of dipstick hematuria 0–3
months after the INR 43.0 compared with 0–3 months
before the INR 43.0.
Concurrent medication and WRN
We assessed whether the medications that were being
prescribed at the onset of the INR 43.0 might represent
risk factors for WRN. The hypothesis is that the risk of WRN
is increased by medications that increase glomerular hydro-
static pressure (PG), increase glomerular permeability, or
increase coagulopathy. Table 3 shows the association of such
medications with the risk of WRN. For this exploratory
analysis, we did not stratify by CKD, no-CKD status, and did
not account for whether the patient received medications in
more than one-drug category.
The drugs that affect blood pressure were arbitrarily
classified as those that may lower or raise PG. As shown in
Table 3, the use of drugs that affect blood pressure was more
common in WRN than no-WRN patients. This may reflect
greater use of antihypertensive drugs in the CKD cohort,
which had a higher risk of WRN than the no-CKD cohort.
Consistent with our hypothesis that drugs that increase
PG increase the risk of WRN is that use of the drugs in this
class was 58% higher in WRN patients than the no-WRN
patients (38 versus 25%, Po0.001). However, the use of
drugs that may lower PG was also higher in WRN than no-
WRN patients (59 versus 52%, P¼ 0.002). But the use was
only 13% higher, and this could be explained by the greater
use of this category of drugs in CKD, and CKD carries a
greater risk of WRN.
Statins decrease glomerular capillary permeability (dec-
rease proteinuria) and, for this reason, might protect against
WRN. However, statin use was not significantly associated
with the risk of WRN.
Among drugs that affect coagulation, aspirin use
was significantly greater in WRN than no-WRN patients
(35 versus 28%, P¼ 0.001). This is consistent with the notion
that aspirin therapy contributes to coagulopathy and, there-
fore, the risk of WRN. However, heparin use was less in
WRN than no-WRN patients (47 versus 51%, P¼ 0.001).
This paradox could be explained if the heparin use in those
initiating warfarin therapy was discontinued just before the
onset of the INR 43.0.
Survival rate and WRN
Figure 5a shows that 5-year Kaplan–Meier survival rate was
significantly lower in WRN than no-WRN patients (58 versus
73%, respectively; Po0.001), with survival differences being
more pronounced shortly after the episode of INR 43.0
(1-year survival was 68.9% in WRN versus 81.1% in
no-WRN patients, P¼ 0.049). Figure 5b shows survival rate
stratified according to CKD, no-CKD status. The trend was
the same: WRN CKD patients had decreased survival rate
compared with no-WRN CKD patients (P¼ 0.064). Figure 5c
used the univariate Cox model with survival as a time-
varying covariate to estimate the hazard ratio for death in
the WRN versus no-WRN cohorts, with 95% confidence
intervals at selected early time points. The hazard for death
(WRN versus no WRN) was highest within the first weeks
after the INR 43.0 (hazard ratio at 1 week¼ 3.65, 95%
confidence interval: 2.81, 4.75). Thereafter the hazard rate
decreased progressively until it reached non-significant levels
6 months later.
Figure 5d shows the significance of WRN versus no WRN
as a predictor of survival after controlling for covariates that
were significantly associated with WRN: age at INR 43.0,
CKD, diabetes mellitus, heart failure, and glomerulonephri-
tis. There were no significant two-way interactions between
the WRN and no-WRN patients with any of the covariates.
Thus, WRN was a significant predictor of death after
controlling for all of these covariates. Similar to the non-
adjusted model, the maximal hazard ratio for the adjusted
model was at the first week after INR 43.0 (hazard ratio:
3.19, 95% confidence interval: 2.45, 4.15) and steadily
declined over time.
DISCUSSION
To the best of our knowledge, this is the first and the only
large-scale study of the newly recognized syndrome, WRN.
Table 1 | Baseline clinical characteristics of cohort 5 (the final
cohort) stratified by WRN or no WRN
Variable Level
WRN: DSC
X0.3, n=821 (%)
No WRN: DSC
o0.3, n=3185 (%) P-value
Age at INR 43.0 Mean±s.d. 63.6±14.7 61.7±15.6 0.0049
Sex Female 356 (43) 1534 (48) 0.0840
Male 465 (57) 1651 (52)
Racea White 625 (78) 2503 (79)
Black 173 (21) 607 (19)
Asian 0 (0) 17 (1) 0.2102
Native
American
0 (0) 4 (0)
Other 8 (1) 19 (1)
CKD No 516 (63) 2580 (81) o0.0001
Yes 305 (37) 605 (19)
Diabetes No 433 (53) 2004 (63) o0.0001
Yes 388 (47) 1181 (37)
Diabetic
nephropathy
No 741 (90) 3054 (96) o0.0001
Yes 80 (10) 131 (4)
Hypertension No 153 (19) 880 (28) o0.0001
Yes 668 (81) 2305 (72)
Heart failure No 315 (38) 1848 (58) o0.0001
Yes 506 (62) 1337 (42)
Glomerulo-
nephritis
No 786 (96) 3134 (98) o0.0001
Yes 35 (4) 51 (2)
Nephrotic
syndrome
No 801 (98) 3159 (99) 0.0008
Yes 20 (2) 26 (1)
Polycystic
kidneys
No 795 (97) 3109 (98) 0.3248
Yes 26 (3) 76 (2)
Abbreviations: CKD, chronic kidney disease; INR, international normalized ratio;
SC, serum creatinine; WRN, warfarin-related nephropathy.
aData is not available for 50 patients.
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Our first study of WRN was a renal biopsy study of patients
with warfarin coagulopathy who developed unexplained AKI.
The kidney biopsy findings indicated that the AKI was
attributable to widespread glomerular hemorrhage causing
obstructive red blood cell cast formation.1 Next, we under-
took a retrospective analysis of 103 warfarin-treated CKD
patients followed up in our nephrology practice.2 We found
that 37% of the patients who experienced an INR 43.0
acutely developed an unexplained acute increase in SC
X0.3mg/dl (mean increase 0.61±0.44mg/dl). Thereafter,
these patients showed accelerated progression of their CKD.2
None of these patients underwent kidney biopsy. The present
study was undertaken to obtain a clearer understanding of
WRN’s prevalence, risk factors, and outcomes in both CKD
and no-CKD patients. The present study considered all of the
patients at the OSUMC who received warfarin therapy during
the 5-year period starting January 2005. From this cohort of
15,258 patients, we selected 4006 patients who met the
study’s inclusion and exclusion criteria. The large number of
patients in the study cohort precluded a detailed assessment
of whether an acute increase in SC in relation to an acute
increase in INR to43.0 was ‘unexplained’. Thus, the present
study describes ‘presumptive’ WRN.
We found that of the 4006 patients who experienced an
INR 43.0, 20.5% developed presumptive WRN (an increase
in SC toX0.3mg/dl coincident with INR43.0 in absence of
evidence of hemorrhage). Among the CKD patients, the
incidence of presumptive WRN was 33%, which is compar-
able to the 37% incidence of WRN that we previously
reported in our warfarin-treated CKD patients.2 In those
patients, a detailed assessment of each patient’s clinical record
allowed a determination as to whether the increase in SC was
unexplained. The good agreement between the present study
and our previous study with regard to the incidence of WRN
suggests that the presumptive WRN of the present study
largely represents WRN.
Among the no-CKD patients, the incidence of presump-
tive WRN was 16.5%. Thus, presumptive WRN (and by
inference WRN) is remarkably common. This begs the question
as to why such a common complication of warfarin therapy has
Table 2 | Baseline clinical characteristics of WRN and no-WRN patients according to CKD or no-CKD status
No CKD (n=3096) CKD (n=910)
Variable Level
WRN: DSC X0.3,
n=516 (%)
No WRN: DSCo0.3,
n=2580 (%) P-value
WRN: DSC X0.3,
n=305 (%)
No WRN: DSCo0.3,
n=605 (%) P-value
Age at INR spike Mean±s.d. 61.9±14.8 60.9±15.7 0.1837 66.5±14.0 54.9±14.9 0.1093
Gender Female 236 (46) 1280 (50) 0.1079 120 (39) 254 (42) 0.4450
Male 280 (54) 1300 (50) 185 (61) 351 (58)
Racea White 412 (81) 2093 (82) 0.0947 213 (71) 410 (68) 0.6550
Black 87 (17) 420 (16) 86 (29) 187 (31)
Asian 0 (0) 16 (1) 0 (0) 1 (0)
Native American 0 (0) 4 (0) 0 (0) 0 (0)
Other 8 (2) 18 (1) 0 (0) 1 (0)
Diabetes No 305 (59) 1757 (68) o0.0001 128 (42) 247 (41) 0.7414
Yes 211 (41) 823 (32) 177 (58) 358 (59)
Diabetic No 495 (96) 2551 (99) o0.0001 246 (81) 503 (83) 0.3538
nephropathy Yes 21 (4) 29 (1) 59 (19) 102 (17)
Hypertension No 126 (24) 827 (32) 0.0006 27 (9) 53 (9) 0.9630
Yes 390 (76) 1753 (68) 278 (91) 552 (91)
Heart failure No 257 (50) 1647 (64) o0.0001 58 (19) 201 (33) o0.0001
Yes 259 (50) 933 (36) 247 (81) 404 (67)
Glomerular nephritis No 502 (97) 2558 (99) 0.0003 284 (93) 576 (95) 0.1911
Yes 14 (3) 22 (1) 21 (7) 29 (5)
Nephrotic syndrome No 511 (99) 2570 (100) 0.0825 290 (95) 589 (97) 0.0743
Yes 5 (1) 10 (0) 15 (5) 16 (3)
Polycystic kidneys No 504 (98) 2535 (98) 0.3698 291 (95) 574 (95) 0.7259
Yes 12 (2) 45 (2) 14 (5) 31 (5)
Abbreviations: CKD, chronic kidney disease; INR, international normalized ratio; SC, serum creatinine; WRN, warfarin-related nephropathy.
aData is not available for 50 patients.
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Figure 4 |Changes in the hematuria grade in patients with
and without warfarin-related nephropathy (WRN). Hematuria
was graded using a semiquantitative scale of 0 to 3þ . Grade 0, no
hematuria; 1þ , mild hematuria; 2þ , moderate hematuria; and
3þ , large hematuria. Panel a shows changes in the hematuria
grade in the WRN and no-WRN patients. The difference in
hematuria grade at 1 week post-INR43.0 and 0–3 months before
the INR 43.0 was calculated, and the percentage of patients
whose hematuria grade was changed is shown. Consecutive data
were available in only 732 patients. Panel b shows changes in the
hematuria grade in the WRN and no-WRN patients at 0–3 months
after INR 43.0 and 0–3 months before INR 43.0. Consecutive
data were available for only 771 patients. None of the differences
shown in panel a or b was significant. a.u., arbitrary unit.
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been unrecognized until just recently. The reasons could include
the following: first, WRN is not part of the lexicon of causes of
AKI. Although we5 and others6 had reported single cases of
acute renal failure associated with severe warfarin glomerulo-
pathy in which the renal biopsy confirmed extensive red blood
cell cast formation, there was no compelling reason to believe
from these case reports that lesser degrees of warfarin
coagulopathy could cause AKI. That notion, however, was
dispelled by our renal biopsy study of nine cases of AKI
associated with relatively mild warfarin coagulopathy1 and by
our retrospective analysis of the warfarin-treated CKD patient
followed up in our nephrology program.2 Second, although
WRN can occur in the same patient,1 the retrospective analysis
of our warfarin-treated CKD patients indicated that WRN
usually occurs early in the course of warfarin therapy. Thus, at
any given time, the prevalence of acute WRN among all
warfarin-treated patients is relatively low. Third, as demon-
strated in the present study, WRN is associated with a
substantial increase in mortality rate. Thus, patients susceptible
to WRN are underrepresented in the population of warfarin-
treated patients. Fourth, as demonstrated in the present study,
the risk of WRN is particularly great in high-risk patients who
have multiple risk factors for AKI. Because of the multiplicity of
these risks, the presence of WRN was not easily recognized.
Fifth, nephrologists might be reluctant to perform a kidney
biopsy in patients receiving warfarin, because of the increased
risk of hemorrhage.
The present work helps confirm our previous work that
WRN does not require severe warfarin coagulopathy. Indeed,
each of our three WRN studies shows that the average INR in
the WRN cohorts were in the low to mid-4 range, with no
clinically important differences in INR level between the
CKD and no-CKD cohorts. The higher risk of WRN in CKD
patients may be due to their higher likelihood of having a
supratherapeutic INR.7 Indeed, in our study, we found INR
to be slightly but significantly higher in WRN patients than
in no-WRN patients. However, among CKD patients, INR
levels were similar in WRN and no-WRN patients. There was
no significant correlation between the degree of INR
elevation and the magnitude of SC increase in any of the
study groups. Also, we did not find a difference in the INR
levels between WRN and no-WRN patients in our previous
study (103 patients with CKD).
The present work is also the first to show that WRN is
associated with a substantially decreased survival rate. This
finding is consistent with the previous reports of increased
mortality rate in warfarin-treated chronic hemodialysis
patients.8,9 Although it is clear that the increased mortality
rate associated with WRN is related to the comorbidities of
diabetes, hypertension, and cardiovascular disease, how these
comorbidities are related to the mechanisms of death in these
patients remain to be elucidated.
The present work also provides new insights into the
possible mechanisms of the AKI of WRN. Specifically, in
exploratory studies, we show that therapies that tend to
increase glomerular hydrostatic pressure are associated with
an increased risk of WRN. In addition, concomitant aspirin
therapy is associated with an increased risk of WRN. Both of
these findings are consistent with the notion that glomerular
hemorrhage causing tubular obstruction may be the
dominant mechanism of the AKI associated with WRN.
However, there are other possible mechanisms by which
warfarin therapy could promote AKI, including atheroem-
bolism,10 interstitial nephritis,11 and direct effects of warfarin
on the glomerulus.12 Consistent with this notion is the
finding that coagulopathy alone is not responsible for WRN
in that gross hematuria is unusual, as suggested by this and
our previous study.2
The limitations of the present work are those of a
retrospective study in which the testing protocol was not
prespecified. Thus, this work suffers from ascertainment bias.
Of particular concern is that in order to be included in our
analysis, we required a recorded SC by 1 week after the onset
of INR 43.0. Frequent measurement of SC is more likely
Table 3 | Association of concurrent therapy with the patient’s status as WRN or no WRN
Medication group
WRN: DSC X0.3,
n=821 (%)
No WRN: DSC o0.3,
n=3185 (%) P-value
Drugs that affect blood pressure 555 (68) 1787 (56) o0.001
Drugs that may lower glomerular hydrostatic pressure (e.g., ACE inhibitors, angiotensin
receptor blockers, b-blockers, diuretics, non-dihydropyridine CCB, clonidine)
484 (59) 1653 (52) 0.002
Drugs that may raise glomerular hydrostatic pressure (e.g., dihydropyridine CCB, direct-acting
smooth muscle relaxants (hydralazine), potassium channel agonists (minoxidil), b-2-adrenergic
receptor agonist (albuterol), erythropoietin, endothelin receptor antagonist (bosentan),
dobutamine)
311 (38) 780 (24) o0.001
Antilipemic drugs 167 (20) 550 (17) 0.243
Statins 145 (18) 473 (15) 0.243
All other classes of antilipemic drugs 32 (4) 125 (4) 0.972
Drugs that affect the coagulation system 513 (62) 1882 (59) 0.307
Aspirin 287 (35) 897 (28) 0.001
Non-steroidal anti-inflammatory drugs 36 (4) 153 (5) 0.307
Clopidogrel, ticlopidine 63 (8) 214 (7) 0.307
Heparin 387 (47) 1627 (51) 0.001
Abbreviations: ACE, angiotensin-converting enzyme; CCB, calcium channel blockers; SC, serum creatinine; WRN, warfarin-related nephropathy.
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in sicker patients. Thus, our study may have identified the
sickest patients with INR 43.0. Consistent with that notion
is the high percent of the WRN and no-WRN cohort that had
associated diabetes and cardiovascular disease. Nevertheless,
even if all of the cases of WRN and its mortality in our study
were identified because of ascertainment bias, WRN is still a
major problem because cohort 5 was 26% of cohort 1. Also,
our analysis of comorbidities and the risk of WRN indicate
that WRN is an independent risk factor for increased
mortality. Another limitation of this retrospective study is
that there was no consistent testing of proteinuria around the
time of the INR spike. Thus, we could not broadly test
whether proteinuria itself was a risk factor for WRN.
To clearly establish the risk factors for WRN and its
consequences will require a prospective study. We suggest
that the present work provides compelling reasons to proceed
with the prospective study.
In summary, warfarin is the most widely used anticoagulant to
treat or prevent thrombotic complications. Currently, more than
30 million prescriptions for warfarin are filled annually in the
United States.13 The present work provides clear evidence that
warfarin coagulopathy is associated with a substantial increase in
risk of AKI and acute mortality, especially in CKD patients. This
AKI is independent of systemic hemorrhage. The mechanisms of
these risks and how they might be mitigated will require further
study. Nevertheless, we suggest that the evidence is sufficiently
compelling to justify special precautions in managing warfarin
therapy to minimize the risks of WRN. This recommendation is
especially relevant to the CKD patients.
MATERIALS AND METHODS
We analyzed the de-identified data of consecutive patients who had
initiated warfarin therapy during the period 1 January 2005 to 31
December 2009 at the OSUMC. The data were obtained from the
OSUMC IW with approval of the OSU Institutional Review Board. A
multistep algorithm was utilized to identify patients with presumptive
WRN. The analysis reported here was performed on cohort 5 (the final
cohort). The algorithm used to select cohort 5 is as follows:
a. Cohort 1 (N¼ 15,258). This consisted of all patients who had at least
one order for warfarin, Coumadin, Jantoven, Marevan, Lawarin, or
Waran with an order activation date between 1 January 2005 and 12
December 2009 based on the records of the OSUMC IW (prisoners
and patients o18 years of age at discharge were excluded).
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Figure 5 | Survival analysis and hazard ratio in patients with and without warfarin-related nephropathy (WRN) and chronic kidney
disease (CKD). Panel a: Kaplan–Meier plot (log-rank P-valueo0.0001) for WRN patients (N¼ 3179, black dotted line) and no-WRN patients
(N¼ 810, black solid line). Panel b: Kaplan–Meier plot (log-rank P-value o0.0001) for patients with WRN and no WRN, stratified by CKD,
no-CKD status. Patients with WRN and CKD (black dotted line) had the lowest survival rate. Patients with WRN but no CKD had better
survival rates (gray solid line). Patients without WRN, but with CKD had better survival rates compared with WRN patients with CKD
(black dashed line). Patients without both WRN and CKD had the best survival rate (black solid line). Panel c: the univariate Cox model with
survival as a time-varying covariate was used to estimate the hazard ratio for death in the WRN versus no-WRN cohorts, with 95%
confidence intervals (CIs) at selected early time points. Because violation of the assumption of proportional hazards, WRN and no-WRN
status was included as a time-varying covariate in the model. As shown, the hazard ratio for death (WRN versus no WRN) was highest within
the first week after international normalized ratio (INR) 43.0. Thereafter it decreased progressively until it reached non-significant
levels 6 months later. Estimated hazard ratio (solid black line) with 95% CIs (gray lines) is shown. Panel d shows the hazard ratio described in
panel c but adjusted for the covariates that were significantly different between the WRN and no-WRN cohorts: age at INR 43.0, CKD,
diabetes mellitus, heart failure, atrial fibrillation, and glomerulonephritis. The adjusted hazard ratio is similar to that of the unadjusted
hazard ratio. Also, there was no evidence of an interaction between WRN, no-WRN status, and CKD status (P¼ 0.2102). Estimated
hazard ratio (solid black line) with 95% CIs (gray lines) is shown.
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b. Cohort 2 (N¼ 6019). This consisted of all of the patients who
had at least one episode of INR 43.0 recorded. If multiple
episodes of INR 43.0 occurred, we used the first one for the
present analysis.
c. Cohort 3 (N¼ 4848). This consisted of all the patients who had
SC recorded within 1 week after the first INR 4 3.0.
d. Cohort 4 (N¼ 4816). This consisted of all the patients who
had SC recorded within 3 months before the first abnormal
INR 43.0. From cohort 4, we censored those who had, based
on ICD-9 codes, end-stage renal disease (ICD-9 code 585.6) or
evidence of clinically relevant hemorrhage (gastrointestinal tract
hemorrhage, esophageal varices hemorrhage, rectal hemorrhage,
placenta previa hemorrhage, associated with coagulation defi-
ciency hemorrhage) within the first week after INR43.0 (ICD-9
codes 456.0, 459.0, 569.3, 578.9, 641.1, and 641.30). These steps
yielded cohort 5.
e. Cohort 5 (final cohort; N¼ 4006). This cohort was the object of the
present study. This cohort was stratified into CKD or no CKD using
the ICD-9 codes 581.1, 581.2, 581.3, 581.4, and 581.5, which identify
the five stages of CKD according to the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative.14
Analytical studies
All laboratory testing was performed in the clinical laboratories of
the OSUMC. The clinical pathology laboratory at the OSUMC is
using a Beckman Unicel DxC 800 Chemistry Analyzer (Brea, CA)
to measure SC levels. The SYNCHRON System(s) (Brea, CA)
determine creatinine concentration by means of the Jaffe rate
method. A precise volume of sample (16.5ml serum or 5.5ml urine)
is injected in a reaction cup containing an alkaline picrate solution.
The ratio used is one part sample to 35 parts reagent for serum, and
one part sample to 105 parts reagent for urine. Creatinine from the
sample combines with the reagent to produce a red color complex.
Absorbance readings are taken at 520 nm between 19 and 25 s after
sample injection. The absorbance rate has been shown to be a direct
measure of the concentration of creatinine in the sample. The
calibration method used for the creatinine assay is certified by the
manufacturer to be traceable to isotope dilution–mass spectrometry
as the gold standard.
Hematuria was graded using the dipstick semiquantitative scale
of 0–3þ . Grade 0, no hematuria; 1þ , mild hematuria; 2þ ,
moderate hematuria; and 3þ , large hematuria.
Statistical methods
Demographics were first summarized for groups 1 and 2 separately.
The w2- tests were used to assess differences in categorical variables
between groups; a two-sample t-test was used for age. Holm’s
P-value adjustment was used to control type I error when testing for
differences in INR, SC, and eGFR between WRN and no WRN
shown in Figures 1 and 2 (ref. 15). Logistic regression models were
used to assess the significance of the interaction between group and
CKD status for all binary variables (diabetes, diabetic nephropathy,
hypertension, heart failure, glomerular nephritis, nephrotic syn-
drome, polycystic kidneys, and atrial fibrillation). Similarly, a linear
regression model was used to assess the interaction between group
and CKD status for age at INR spike (Table 2). For the exploratory
lab analyses, repeated measures models were used to assess trends in
measurements over time (Figures 1 and 2). For the survival analysis,
Kaplan–Meier plots were first produced, and then a Cox model was
fitted to the data. The model-building process was performed as
described in Moeschberger and Klein,16 Chapters 8 and 9. The
model fit was evaluated as described in Chapter 11 of the same book.
Because of violation of the assumption of proportional hazards,
group was included as a time-varying covariate in the model. The
estimated hazard ratio plot is shown in Figure 4d. We checked for
the significance of group as a predictor of survival, controlling for
the following covariates: age at INR spike, CKD, diabetes, diabetic
nephropathy, heart failure, atrial fibrillation, and glomerular
nephritis. None of the interactions of these variables and group
was significant. These covariates were all significant in the final
model as well as group.
Two-sample t-tests were performed to compare INR between
WRN and no WRN as explorative analyses for the overall sample
and CKD/non-CKD subgroups.
All analyses were performed using SAS/STAT software, version
9.2 (SAS Institute, Cary, NC).
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